# GLAXO (GLAXO) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/glaxo

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,826
- Change: +0.93%
- As of: 2026-09-18
- 1D return: +1.39%
- 5D return: -0.07%
- 1M return: -5.36%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Glaxo's stock is trading at ₹2838.8, exhibiting a mixed technical stance across different timeframes. Daily and monthly indicators suggest a bearish trend, with the Supertrend indicator pointing downwards on both these periods. However, the weekly timeframe shows a bullish trend, with the Supertrend indicator in an upward direction and the price trading above key moving averages like the 20-day and 50-day SMAs. The daily chart shows the price below the 20-day EMA and SMA, indicating short-term weakness, while being above the 50-day EMA and SMA, suggesting some underlying support.

Nearest support is observed around ₹2818.9, with further levels at ₹2775.5 and ₹2751.1. Overhead resistance is noted at ₹2843.3, followed by ₹2886.7. The stock's current position is within its 20-period range, approximately 23% of the way up, and further out at 73% of its 252-period range, indicating it is closer to the upper end of its longer-term trading band. Recent market activity shows a balance of positive and neutral events over the last 30 days, with no downside events recorded.

The stock's setup carries a risk profile with an annualized volatility of 35% and a current drawdown of -18%. The Average True Range (ATR) as a percentage of price is 3.1%. Key watch conditions include monitoring the price action around the ₹2843.3 resistance level. A sustained break above this could signal strengthening momentum, while a move below the ₹2818.9 support level may indicate further downside pressure.

- Stock closed at ₹2838.8 on September 18, 2026.
- Daily and monthly Supertrend indicators are bearish; weekly Supertrend is bullish.
- Nearest support level is ₹2818.9; nearest resistance is ₹2843.3.
- Current drawdown is -18% with annualized volatility at 35%.
- Watch for price movement above ₹2843.3 resistance or below ₹2818.9 support.

- Inside Bar
- Morning Star
- Outside Bar
- Doji
- Bearish Engulfing Reversal

### News Context

GlaxoSmithKline Pharmaceuticals Limited shareholders approved key management appointments via postal ballot, with resolutions for Ms. Karine J F Natland as Non-Executive Director and Mr. Bhushan Akshikar as Managing Director receiving strong backing. The voting period concluded on September 13, 2026, with over 99.71% approval for both appointments. This follows a corrigendum issued on September 1, 2026, to a postal ballot notice dated August 3, 2026, which clarified a typographical error regarding Mr. Akshikar's monthly basic salary, correcting it to ₹24,00,000 from an incorrectly stated ₹24,00,0000. In a separate development, the company received a tax refund of ₹4,99,11,100 on August 18, 2026, related to the Assessment Year 2025-2026, with no reported violations in connection with the assessment.

- Shareholders approved the appointment of Ms. Karine J F Natland as Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director with over 99.71% approval via postal ballot, concluded September 13, 2026.
- A corrigendum was issued on September 1, 2026, to a postal ballot notice dated August 3, 2026, correcting Mr. Akshikar's monthly basic salary to ₹24,00,000.
- GlaxoSmithKline Pharmaceuticals Limited received a tax refund of ₹4,99,11,100 on August 18, 2026, for Assessment Year 2025-2026.

- GlaxoSmithKline Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting
- GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026 |SUBJECT: General Updates
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates

### What Changed

As of September 18, 2026, Glaxosmithkline Pharmaceuticals on the NSE has seen a slight increase in its stock price, moving from ₹2799.9 to ₹2838.8. This change occurred between an unstated prior observation date and the current report date of September 18, 2026. No new filings or news developments were reported for the company during this period. The company's profile as Glaxosmithkline Pharmaceuticals listed on the NSE remains unchanged.

- Stock price increased from ₹2799.9 to ₹2838.8 as of September 18, 2026.
- No new filings were reported as of September 18, 2026.
- No new news developments were reported as of September 18, 2026.
- The company continues to be listed as Glaxosmithkline Pharmaceuticals on the NSE.

### Official Filings

GlaxoSmithKline Pharmaceuticals Limited shareholders approved key leadership appointments via postal ballot on September 13, 2026. Ms. Karine J F Natland was appointed as a Non-Executive Director, and Mr. Bhushan Akshikar was re-appointed as Managing Director. Both resolutions passed with a high approval rate of 99.71%. The voting period for these resolutions, which involved remote e-voting, ran from August 14 to September 13, 2026. Earlier, on August 19, 2026, the company reported receiving a tax refund of ₹4,99,11,100 for the Assessment Year 2025-2026, which was credited on August 18, 2026. Additionally, on August 6, 2026, the company announced a tax refund of ₹52 crore from the Income Tax Appellate Tribunal for assessment year 1984-85, along with interest income of ₹42.09 crore on this refund.

- Shareholders approved the appointment of Ms. Karine J F Natland as Non-Executive Director and re-appointment of Mr. Bhushan Akshikar as Managing Director via postal ballot on September 13, 2026, with 99.71% approval.
- The postal ballot voting period was from August 14, 2026, to September 13, 2026.
- A tax refund of ₹4,99,11,100 for Assessment Year 2025-2026 was received and credited on August 18, 2026.
- A refund of ₹52 crore from the Income Tax Appellate Tribunal for assessment year 1984-85 was received on August 6, 2026, with associated interest income of ₹42.09 crore.

- GlaxoSmithKline Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting
- GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026 |SUBJECT: General Updates
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting
- GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL
- GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Action(s) taken or orders passed (sub-para 20) |SUBJECT: Actions initiated/taken or orders passed-XBRL

### Fundamentals

Glaxosmithkline Pharmaceuticals, listed on the NSE, reported its financial results for the periods ending in FY2025-26 and Q1 FY2026-27. Revenue from operations showed a sequential decline, moving from ₹1,041.26 crore in Q3 FY2025-26 to ₹995.30 crore in Q4 FY2025-26, and further to ₹938.44 crore in Q1 FY2026-27. Profitability metrics followed a similar downward trend. Profit Before Exceptional Items And Tax decreased from ₹381.95 crore in Q3 FY2025-26 to ₹373.10 crore in Q4 FY2025-26, and then to ₹322.45 crore in Q1 FY2026-27. Profit Before Tax and Profit Loss For Period also mirrored this pattern, with Profit Loss For Period falling from ₹295.62 crore in Q3 FY2025-26 to ₹237.18 crore in Q1 FY2026-27. Basic Earnings Per Share (EPS) also declined sequentially, from ₹16.54 per share in Q3 FY2025-26 to ₹14 per share in Q1 FY2026-27. Other Expenses fluctuated, decreasing from ₹154.22 crore in Q3 FY2025-26 to ₹135.62 crore in Q4 FY2025-26, before rising to ₹155.96 crore in Q1 FY2026-27. Investors may wish to monitor revenue trends and the relationship between operating expenses and profitability in upcoming periods.

- Revenue from operations decreased sequentially from ₹1,041.26 crore in Q3 FY2025-26 to ₹938.44 crore in Q1 FY2026-27.
- Profit Loss For Period declined from ₹295.62 crore in Q3 FY2025-26 to ₹237.18 crore in Q1 FY2026-27.
- Basic Earnings Per Share (EPS) fell from ₹16.54 per share in Q3 FY2025-26 to ₹14 per share in Q1 FY2026-27.
- Other Expenses were ₹154.22 crore in Q3 FY2025-26, ₹135.62 crore in Q4 FY2025-26, and ₹155.96 crore in Q1 FY2026-27.

### Bull Case

The company's stock has shown positive performance over several periods, indicating potential investor interest. On a weekly timeframe, technical indicators suggest a bullish trend, with the Supertrend indicator pointing upwards and the 20-day Exponential Moving Average (EMA) showing a positive slope. This is supported by a notable increase in the 3-month return of 25% and a 6-month return of 16%. The year-to-date return also stands at 16%, further reinforcing a constructive short-to-medium term view. The stock's proximity to a support level at ₹2818.9, which is 0.7% below the current price, suggests a potential floor for trading.

- The stock has a positive year-to-date return of 16% as of 2026-09-18.
- The 3-month return was 25% and the 6-month return was 16%, as of 2026-09-18.
- On a weekly basis, the Supertrend indicator is bullish, and the 20-day EMA slope is positive.
- The nearest support level is ₹2818.9, which is 0.7% below the current price of ₹2838.8.

### Bear Case

Glaxosmithkline Pharmaceuticals' technical indicators suggest a bearish trend. The daily Super Trend is indicating a 'bearish' direction, and the 20-day Exponential Moving Average (EMA) slope is negative, pointing downwards. While the monthly Super Trend is also bearish, the weekly trend shows a 'bullish' Super Trend direction. The stock has experienced a drawdown of 18% from its recent peak, and its maximum drawdown stands at 39%. The annualized volatility is 35%, and the Average True Range (ATR) as a percentage of the price is 3.1%.

- The daily Super Trend indicator is in a 'bearish' state as of September 18, 2026.
- The stock has a current drawdown of -18% and a maximum drawdown of -39%.
- Annualized volatility is recorded at 35%.

### FAQs

**What were the recent shareholder approvals regarding director appointments?**

On September 13, 2026, GlaxoSmithKline Pharmaceuticals Limited shareholders approved the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. The approvals were granted via postal ballot with a 99.71% approval rate. A total of 143,066,813 votes were in favor of Ms. Natland's appointment and 143,025,237 votes were in favor of Mr. Akshikar's re-appointment, out of 169,406,034 outstanding shares.

**What was the outcome of the tax refund received by the company?**

GlaxoSmithKline Pharmaceuticals Limited received a tax refund of ₹4,99,11,100 on August 18, 2026, following an intimation under section 143(1) of the Income Tax Act for the Assessment Year 2025-2026. The company reported no violations or contraventions in connection with this assessment, and the amount will be recorded in the Tax Paid Assets account.

**What is the current technical trend and key price levels for GlaxoSmithKline Pharmaceuticals?**

As of September 18, 2026, the daily trend for GlaxoSmithKline Pharmaceuticals shows a bearish Supertrend at 3069.28, with the closing price at ₹2838.8. The weekly trend, however, indicates a bullish Supertrend at 2477.97. Key support levels are identified at ₹2818.9 (pivot) and ₹2775.5, while resistance levels are noted at ₹2843.3 and ₹2886.7.

**What was the correction made to the postal ballot notice regarding Mr. Akshikar's salary?**

On September 1, 2026, GlaxoSmithKline Pharmaceuticals Limited issued a corrigendum to its August 3, 2026 postal ballot notice. The correction clarified a typographical error in the basic salary figure for Mr. Akshikar, stating the correct monthly basic salary is ₹24,00,000, amending the previously published incorrect figure of ₹24,00,0000.

- GlaxoSmithKline Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting
- GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026 |SUBJECT: General Updates
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹2,818.9
- Risk regime: Price Risk Requires Attention

### Support levels
- 2615.653125
- 2518.609765625
- 2458.496875

### Resistance levels
- 2893.05
- 2975.95
- 3067.10625

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.39% |
| return_10 | -3.36% |
| return_1m | -1.34% |
| return_1y | +3.03% |
| return_20 | -5.36% |
| return_3m | +25.27% |
| return_5 | -0.07% |
| return_6m | +16.46% |
| return_since_start | +27.18% |
| return_ytd | +15.59% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -39.32% |
| annualized_volatility | +35.11% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Profit Rise Year-on-Year but Decline Sequentially; Inventory Drawdown and Rising Other Expenses Shape the Quarter

GlaxoSmithkline Pharmaceuticals Limited reported revenue of ₹938.44 crore for the first quarter of FY2026-27, a 16.55% increase over the same quarter last year. Net profit rose 15.7% to ₹237.18 crore. Compared to the immediately preceding quarter, revenue and profit declined, while other expenses grew faster than revenue. A reduction in finished goods inventory helped contain total costs for the quarter.

## Revenue Performance
Revenue from operations reached ₹938.44 crore in the quarter ended 30 June 2026. This was 16.55% higher than the ₹805.17 crore recorded in Q1 of the previous fiscal year. On a sequential basis, revenue fell 5.71% from ₹995.30 crore in Q4 FY2025-26. In the prior fiscal year, Q1 was the lowest-revenue quarter, with higher revenue in each of the following three quarters. The current quarter’s decline from Q4 is consistent with that pattern.

## Profitability and Margins
Profit Before Tax (PBT) stood at ₹322.45 crore, a year-on-year increase of 15.58% from ₹278.98 crore. Sequentially, PBT declined 13.58% from ₹373.10 crore in Q4 FY2025-26. The PBT margin was 34.4% in the current quarter, compared with 37.5% in the previous quarter and 34.7% in Q1 of the prior year. The sequential margin compression reflects that costs did not fall in proportion to the revenue decline.

Net profit for the period was ₹237.18 crore, up 15.7% from ₹205.01 crore a year earlier. The effective tax rate was approximately 26.4% of PBT, compared with 26.5% in the year-ago quarter.

## Expense Components
Among the reported expense items, Other Expenses rose sharply. At ₹155.96 crore, they were 37.18% higher than the ₹113.69 crore in Q1 FY2025-26 and 15.0% higher than the ₹135.62 crore in Q4 FY2025-26. This growth rate exceeded the 16.55% year-on-year revenue increase.

Employee Benefit Expense was ₹159.04 crore and Cost of Materials Consumed was ₹72.95 crore. Finance Costs were ₹0.97 crore, up from ₹0.42 crore a year earlier. Depreciation was ₹15.84 crore.

Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade showed a negative ₹123.63 crore, indicating a reduction in inventory levels. This acted as a credit, lowering total expenses for the quarter.

## Earnings Per Share and Exceptional Items
Basic and diluted earnings per share were both ₹14.00, up from ₹12.10 in the same quarter last year. The equality of basic and diluted EPS indicates no dilutive effect from potential shares. No exceptional items were recorded in the current quarter or in Q1 of the prior year, so the reported profit reflects ongoing operations.

## Management Commentary

GSK India delivered strong Q1 FY27 growth with revenue up 15% YoY to INR 924 crores and PAT rising 24% to INR 253 crores. Management stated this performance reflects continued progress in portfolio transformation, supported by execution excellence and favorable base effects. The innovation portfolio, comprising Oncology and New Respiratory therapies, now accounts for 7% of total sales, driving one-fourth of headline growth compared to 4% in the prior year.

Future outlook remains positive as the company prepares for key pipeline launches such as Blenrep and Arexvy while strengthening supply chain resilience through diversified sourcing. Strategic focus areas include accelerating R&D, simplifying operations through AI and technology, and a long-term vision to double General Medicines' growth engine sales by 2030.

## Key Takeaway
GlaxoSmithkline Pharmaceuticals Limited delivered year-on-year growth in revenue and profit for Q1 FY2026-27. The quarter saw a sequential decline in both top and bottom lines, accompanied by a rise in other expenses that outpaced revenue growth. A reduction in finished goods inventory partially offset costs. The absence of exceptional items provides a clear view of operating performance.

### Ratios

## Official filings

- 2026-09-15 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_15092026125437_Final_outcome.pdf)
- 2026-09-02 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_02092026113108_Regulation_47_-_2nd_September_2026.pdf)
- 2026-09-02 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_02092026113354_PostalBallotNoticeRegulation.pdf)
- 2026-09-02 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_02092026113816_PostalBallotNoticeRegulation.pdf)
- 2026-08-19 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_19082026172838_Disclosure_under_Regulation_30_-_August_19.pdf)
- 2026-08-14 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_14082026164059_Regulation_47.pdf)
- 2026-08-13 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_13082026130307_PostalBallotNoticeRegulation.pdf)
- 2026-08-13 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_1095_WebXMLFile_20260813_143427077.xml)
- 2026-08-06 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited reported Q1 FY2027 results with sales of INR924 crores, a 15% increase year-over-year, and profit after tax of INR253 crores, up 24%. The company's innovation portfolio contributed 7% to total revenue, up from 4% in the prior year. Key growth drivers included the general medicines business, which grew double-digit, and the Shingrix vaccine, which saw 65% growth. The company also highlighted progress in its oncology portfolio with Zejula and Jemperli, and upcoming launches like Belantamab Mafodotin and Arexvy. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_06082026195903_AnalystMeetOutcome_-_Transcript.pdf)
- 2026-08-06 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/AIATOP_1095_WebXMLFile_20260806_195457912.xml)
- 2026-08-06 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20260806_195342328.xml)
- 2026-08-06 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited received a refund of Rs 52.00 Crores on August 6, 2026, related to an order from the ACIT Cir 7(1)(1) for the assessment year 1984-85. The company will credit Rs 42.09 Crores as interest income to its P/L account from this refund. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_06082026195741_Dislcosure_under_Reg_30.pdf)
- 2026-08-05 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited has uploaded a recording of its Analyst / Institutional Investor Meetings on August 5th, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The video file is available at https://india-pharma.gsk.com/en-in/investors/analyst-meets/. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_05082026150712_AnalystMeetOutcome_-_Copy_-_Copy.pdf)
- 2026-08-04 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting revenue from operations of ₹92,442 lakhs standalone and ₹93,844 lakhs consolidated. The company's Board of Directors approved these results on August 3, 2026. Separately, TBO Tek Limited will hold its 20th Annual General Meeting on August 27, 2026, via video conference, and Sundaram Asset Management Company Ltd. appointed Ronak Shah as Associate Fund Manager – Fixed Income effective August 3, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_04082026123946_Regulation_47.pdf)
- 2026-08-04 — Official Filing: GlaxoSmithKline Pharmaceuticals Limited announced the appointment of Karine J F Natland as a Non-Executive Non-Independent Director, effective August 4, 2026. This change was an outcome of a board meeting held on August 3, 2026. Ms. Natland joined GSK in 2024 and leads the product strategy for the General Medicines business, having previously held senior roles at Organon, Merck, and MSD.
- 2026-08-03 — Press Release: GlaxoSmithKline Pharmaceuticals Ltd (GSK India) reported financial results for Q1 FY27 ended June 30, 2026, with revenue at INR 924 crores, a 15% year-over-year increase. Profit After Tax (PAT) grew 24% to INR 253 crores, and EBITDA margins were 32%. The company highlighted strong performance in General Medicines, Respiratory, Vaccines, and Oncology portfolios, with upcoming launches including Blenrep and Arexvy. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026160739_Press_release.pdf)
- 2026-08-03 — Official Filing: GlaxoSmithKline Pharmaceuticals Limited announced on August 3, 2026, that Mr. Subesh Williams resigned as Non-Executive Non-Independent Director due to other professional commitments, with the resignation effective the same day. The company also announced the re-appointment of Mr. Bhushan Akshikar as Executive Director, with the term of appointment being 2 months, effective December 1, 2026.
- 2026-08-03 — Generic Announcement: On August 3, 2026, GSK Pharmaceuticals Limited's Board of Directors approved the un-audited financial results for the first quarter ended June 30, 2026. The board also noted the resignation of Non-Executive Director Mr. Subesh Williams, effective August 3, 2026, and the appointment of Ms. Karine J F Natland as Non-Executive Director. Additionally, Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026160155_outcome.pdf)
- 2026-08-03 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited has uploaded a recording of an analyst/institutional investor meeting to https://india-pharma.gsk.com/en-in/investors/analyst-meets/ on August 3rd, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026204644_AnalystMeetOutcome_-_Copy.pdf)
- 2026-08-03 — Management Change: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO_ROID_94301_KMP_Doc.zip)
- 2026-08-03 — Generic Announcement: On August 3, 2026, GSK Pharmaceuticals Limited's Board of Directors approved the un-audited financial results for the first quarter ended June 30, 2026. The board also noted the resignation of Non-Executive Director Mr. Subesh Williams, effective August 3, 2026, and the appointment of Ms. Karine J F Natland as Non-Executive Director. Additionally, Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026161751_outcome.pdf)
- 2026-08-03 — Generic Announcement: On August 3, 2026, GSK Pharmaceuticals Limited's Board of Directors approved the un-audited financial results for the first quarter ended June 30, 2026. The board also noted the resignation of Non-Executive Director Mr. Subesh Williams, effective August 3, 2026, and the appointment of Ms. Karine J F Natland as Non-Executive Director. Additionally, Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026160920_outcome.pdf)
- 2026-08-03 — Generic Announcement: On August 3, 2026, GSK Pharmaceuticals Limited's Board of Directors approved the un-audited financial results for the first quarter ended June 30, 2026. The board also noted the resignation of Non-Executive Director Mr. Subesh Williams, effective August 3, 2026, and the appointment of Ms. Karine J F Natland as Non-Executive Director. Additionally, Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026161854_outcome.pdf)
- 2026-08-03 — Earnings Presentation: GlaxoSmithKline Pharmaceuticals Limited announced investor and analyst meetings on August 3, 2026, presenting financial results for Q1 FY27. The company reported a revenue of ₹924 crore, a 15% increase year-over-year, and Profit After Tax (PAT) of ₹253 crore, a 24% increase. EBITDA grew 17% to ₹293 crore. The innovation portfolio, including oncology and new respiratory products, contributed significantly to growth. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026160042_AnalystMeetOutcome.pdf)
- 2026-08-03 — Generic Announcement: On August 3, 2026, GSK Pharmaceuticals Limited's Board of Directors approved the un-audited financial results for the first quarter ended June 30, 2026. The board also noted the resignation of Non-Executive Director Mr. Subesh Williams, effective August 3, 2026, and the appointment of Ms. Karine J F Natland as Non-Executive Director. Additionally, Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03082026161636_outcome.pdf)

## News and market events

- 2026-08-18 — Mint: **Stocks to buy for short term: Grasim, Quess Corp among 6 stocks experts recommend buying today for next 1-2 weeks** — Experts suggest capitalising on bullish momentum by targeting six stocks poised for growth over the next 1-2 weeks. With a focus on disciplined risk management, this article reveals key levels and potential upside for smart investors seeking short-term opportunities. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-buy-for-short-term-grasim-quess-corp-among-6-stocks-experts-recommend-buying-today-for-next-1-2-weeks-11787027051128.html)
- 2026-08-03 — CNBC-TV18: **GSK Pharma Q1 profit rises 16% as general medicines, vaccines drive growth** — The company's net profit stood at ₹237.1 crore for the first quarter of FY27, compared with ₹205 crore a year earlier. Revenue from operations increased 16.6% to ₹938 crore from ₹805 crore in the corresponding quarter last year. — [Source](https://www.cnbctv18.com/market/earnings/gsk-pharma-q1-profit-rises-16-as-general-medicines-vaccines-drive-growth-19960572.htm)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)

## Business profile

**Strategic vision:** Develops and delivers medicines and vaccines for global health.

### Business segments
- **Pharmaceuticals and Healthcare:** The company discovers, develops, and delivers medicines and vaccines across four key therapeutic areas. It offers a range of pharmaceutical products in India.

### Competitive strengths
- Research-based approach to medicine and vaccine development.
- Focus on specific therapeutic areas for specialized expertise.

## Related stocks

- [360ONE (Financial Services)](https://faxioms.com/stocks/360one) — +1.96%
- [3MINDIA (Diversified)](https://faxioms.com/stocks/3mindia) — +5.50%
- [AADHARHFC](https://faxioms.com/stocks/aadharhfc) — -1.42%
- [AARTIIND](https://faxioms.com/stocks/aartiind) — +3.19%
- [AAVAS](https://faxioms.com/stocks/aavas) — -1.07%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/glaxo
Markdown representation: https://faxioms.com/stocks/glaxo?render=md